View article

Thesis (M. Sc. in pharm)--Chulalongkorn University, 2000 The objective of this study was to determine pharmacokinetic parameters of amikacin administered by intramuscular route (IM) in infected-CAPD patients, to evaluate whether or not the amikacin concentration in plasma and dialysate within 48 hours following the drug administration could achieve the therapeutic level and whether or not its trough plasma concentration was in the range that claimed to be safe for ototoxicity and to determine the relationship between plasma and dialysate of amikacin concentrations following IM route of administration. Twelve patients who participated in this study performed CAPD four exchange per day with six hours dwell period. Of the 12 infected-CAPD patients, seven patients had peritonitis (58.3%) and five patients had catheter-related infection with no peritonitis (41.7%). The patients received only one dose of IM amikacin 7.5 mg/kg along with continuous IP cefazolin as an empirical treatment. Both plasma and dialysatesamples from the patients were collected within 48 hours. The results showed that all patients had peak plasma concentration of amikacin in the therapeutic range (15-30 mg/L) with the mean peak concentration equaled to 25.3 mg/L and the mean time to peak was at 2.6 hour. The trough plasma concentration of amikacin at 48 hours in all patients were higher than 5 mg/L with the mean concentration equaled to 10.3 mg/L which may cause ototoxicity if this dosage would be given every 48 hours. The mean volume of distribution was 35.99 L (0.56 L/kg), the mean total body clearance was 0.64 L/hr (10.73 ml/min) with the mean half-life …